During the last session, Outlook Therapeutics Inc (NASDAQ:OTLK)’s traded shares were 0.29 million, with the beta value of the company hitting 0.63. At the end of the trading day, the stock’s price was $6.05, reflecting an intraday gain of 5.03% or $0.29. The 52-week high for the OTLK share is $13.32, that puts it down -120.17 from that peak though still a striking 23.8% gain since the share price plummeted to a 52-week low of $4.61. The company’s market capitalization is $143.12M, and the average intraday trading volume over the past 10 days was 0.34 million shares, and the average trade volume was 242.54K shares over the past three months.
Outlook Therapeutics Inc (OTLK) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.14. OTLK has a Sell rating from 0 analyst(s) out of 5 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 5 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.85.
Outlook Therapeutics Inc (NASDAQ:OTLK) trade information
Outlook Therapeutics Inc (OTLK) registered a 5.03% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 5.03% in intraday trading to $6.05, hitting a weekly high. The stock’s 5-day price performance is 11.21%, and it has moved by 15.24% in 30 days. Based on these gigs, the overall price performance for the year is -52.17%. The short interest in Outlook Therapeutics Inc (NASDAQ:OTLK) is 2.99 million shares and it means that shorts have 10.99 day(s) to cover.
Outlook Therapeutics Inc (OTLK) estimates and forecasts
Statistics show that Outlook Therapeutics Inc has outperformed its competitors in share price, compared to the industry in which it operates. Outlook Therapeutics Inc (OTLK) shares have gone down -29.65% during the last six months, with a year-to-date growth rate more than the industry average at 24.17% against 17.10. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 15.00% this quarter and then drop -18.70% in the quarter after that.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 52.49%. While earnings are projected to return 3.43% in 2024.
OTLK Dividends
Outlook Therapeutics Inc is due to release its next quarterly earnings on 2024-Dec-20. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Outlook Therapeutics Inc (NASDAQ:OTLK)’s Major holders
Outlook Therapeutics Inc insiders own 35.58% of total outstanding shares while institutional holders control 35.99%, with the float percentage being 55.86%. ROSALIND ADVISORS, INC. is the largest shareholder of the company, while 89.0 institutions own stock in it. As of 2024-06-30, the company held over 0.45 million shares (or 3.1534% of all shares), a total value of $3.32 million in shares.
